Jade Biosciences IncQ) expected to post a loss of 43 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
Jade Biosciences IncQ) is expected to report a loss of 43 cents per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts maintain a "buy" rating, with a median 12-month price target of $16.50, reflecting a potential upside of 55.6% from the last closing price of $7.32. Recent quarterly performances show mixed results, with several misses and beats in earnings estimates over the past year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments